Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Serum Biomarker Detects Colorectal Cancer Early

By LabMedica International staff writers
Posted on 26 Jun 2013
A noninvasive molecular test has been developed that measures methylation of a gene in tissues and blood sera as a biomarker for the early detection of cancer.

The gene was identified as the syndecan-2 (SDC2) gene, which encodes for the membrane syndecan-2 protein that is known to participate in cell proliferation, cell migration, and is expressed in colon mesenchymal cells.

Scientists at the Yonsei University College of Medicine (Seoul, Republic of Korea) working with colleagues at Genomictree, Inc. (Daejeon, Republic of Korea) performed DNA microarray analysis coupled with enriched methylated DNA using tissues from primary tumors and nontumor tissues from 12 Colorectal Cancer (CRC) patients. After stepwise filtering, they found a set of genes that were highly methylated across all of the CRC tumors, and of particular importance was SDC2. The methylation level of target region of SDC2 assessed in tumor tissue was found to be significantly higher than that from paired adjacent nontumor tissue.

The biomarker was validated by analyzing SDC2 methylation levels in primary tumors and paired-adjacent nontumor tissue samples from 133 CRC patients. The investigators found that in the transcriptional regulatory region of the SDC2 gene, tumor samples showed significantly higher levels of methylation than the control samples. The SDC2 methylation positivity ranged from 92.9% to 100% when samples were stratified according to stages of cancer. The SDC2 biomarker could also be measured in serum samples from CRC patients and healthy individuals.

Fluorescence-based quantitative methylation-specific polymerase chain reaction (qMSP) was used to determine SDC2 methylation in the serum DNA.

TaeJeong Oh, PhD, the lead author of the study said, “The SDC2 methylation test was able to detect 92% for detection of stage I cancer patients indicating that SDC2 is suitable for early detection of CRC where therapeutic interventions have the greatest likelihood of curing the patient from the disease.” Sungwhan An, PhD, CEO of Genomictree and senior author of the study, said, “We are very excited with this result using a small amount of serum DNA from less than 1 mL of blood. I believe a greater volume of blood will further improve the clinical performance of this test. We are currently preparing another set of clinical validation studies evaluating SDC2 methylation in serum DNA from patients with early adenoma.” The study was published on June 7, 2013, in the Journal of Molecular Diagnostics.

Related Links:

Yonsei University College of Medicine
Genomictree, Inc.



Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.